Aspirin for primary prevention of CVD: Are the right people using it?

,; ,; ,; ,; ,; ,; ,

Original Research

Aspirin for primary prevention of CVD: Are the right people using it?

J Fam Pract. 2012 September;61(9):525-533

By

Jeffrey J. Vanwormer, PhD

Robert T. Greenlee, PhD, MPH

Patrick E. McBride, MD, MPH

Paul E. Peppard, PhD

Kristen C. Malecki, PhD

Jianhong Che, RPh, MPH

Javier F. Nieto, MD, PhD

Not always. Aspirin therapy is both underused and overused, the authors found. Their research identified populations most likely to err in either direction, highlighting a need for screening and patient education.

PDF Download

References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.

2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.

3. Sullivan PW, Ghushchyan V, Wyatt HR. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity. 2007;15:3150-3158.

4. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391.

5. Kriekard P, Gharacholou SM, Peterson ED. Primary and secondary prevention of cardiovascular disease in older adults: a status report. Clin Geriatr Med. 2009;25:745-755.

6. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398.

7. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6:95-107.

8. Barnett H, Burrill P, Iheanacho I. Don’t use aspirin for primary prevention of cardiovascular disease. BMJ. 2010;340:c1805.-

9. Sanchez-Ross M, Waller AH, Maher J, et al. Aspirin for the prevention of cardiovascular morbidity. Minerva Med. 2010;101:205-214.

10. S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement. Ann Intern Med. 2009;150:396-404.

11. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796-1801.

12. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52-61.

13. Pignone M, Anderson GK, Binns K, et al. Aspirin use among adults aged 40 and older in the United States results of a national survey. Am J Prev Med. 2007;32:403-407.

14. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among US adults: behavioral risk factor surveillance system. Am J Prev Med. 2006;30:74-77.

15. Sanchez DR, Diez Roux AV, Michos ED, et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol. 2011;107:41-46.

16. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2:e353.-

17. Rodondi N, Vittinghoff E, Cornuz J, et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med. 2005;118(suppl):1288e1-1288e9.

18. Rodondi N, Cornuz J, Marques-Vidal P, et al. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med. 2008;46:137-144.

19. Nieto FJ, Peppard PE, Engelman CD, et al. The Survey of the Health of Wisconsin (SHOW), a novel infrastructure for population health research: rationale and methods. BMC Public Health. 2010;10:785.-

20. D’Agostino RB, Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.

21. Cody RP, Smith JK. Applied Statistics and the SAS Programming Language. New York, NY: Prentice Hall; 2005.

22. Mallonee S, Daniels CG, Mold JW, et al. Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma. J Okla State Med Assoc. 2010;103:254-260.

23. Centers for Disease Control and Prevention (CDC). Prevalence of aspirin use to prevent heart disease—Wisconsin, 1991, and Michigan, 1994. MMWR Morb Mortal Wkly Rep. 1997;46:498-502.

24. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-160.

25. Werner M, Kelsberg G, Weismantel AM. Which healthy adults should take aspirin? J Fam Pract. 2004;53:146-150.

26. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.

27. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-638.

28. VanWormer JJ, Johnson PJ, Pereira RF, et al. The Heart of New Ulm project: using community-based cardiometabolic risk factor screenings in a rural population health improvement initiative. Popul Health Manag. 2012;15:135-143.

29. Jeffreys D. Aspirin: The Remarkable Story of a Wonder Drug. New York, NY: Bloomsbury Publishing; 2005.

30. Smith NL, Psaty BM, Heckbert SR, et al. The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly. J Clin Epidemiol. 1999;52:143-146.

31. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717-722.

ABSTRACT

Purpose Aspirin is recommended for the primary prevention of cardiovascular disease (CVD) in adults at high risk, but little is known about sociodemographic disparities in prophylactic aspirin use. This study examined the association between sociodemographic characteristics and regular aspirin use among adults in Wisconsin who are free of CVD.

Methods A cross-sectional design was used, and data collected from 2008 to 2010. Regular aspirin use (aspirin therapy) was defined as taking aspirin most days of the week. We found 831 individuals for whom complete data were available for regression analyses and stratified the sample into 2 groups: those for whom aspirin therapy was indicated and those for whom it was not indicated, based on national guidelines.

Results Of the 268 patients for whom aspirin therapy was indicated, only 83 (31%) were using it regularly, and 102 (18%) of the 563 participants who did not have an aspirin indication were taking it regularly. In the group with an aspirin indication, participants who were older had higher rates of regular aspirin use than younger patients (odds ratio [OR]=1.07; P<.001), and women had significantly higher adjusted odds of regular aspirin use than men (OR=3.49; P=.021). Among those for whom aspirin therapy was not indicated, the adjusted odds of regular aspirin use were significantly higher among older participants (OR=1.07; P<.001) vs their younger counterparts, and significantly lower among Hispanic or nonwhite participants (OR=0.32; P=.063) relative to non-Hispanic whites.

Conclusions Aspirin therapy is underused by those at high risk for CVD—individuals who could gain cardioprotection from regular use—and overused by those at low risk for CVD, for whom the risk of major bleeding outweighs the potential benefit. Stronger primary care initiatives may be needed to ensure that patients undergo regular screening for aspirin use, particularly middle-aged men at high CVD risk. Patient education may be needed, as well, to better inform people (particularly older, non-Hispanic whites) about the risks of regular aspirin use that is not medically indicated.

Cardiovascular disease (CVD) is the principal cause of death in the United States.¹ As the population grows older and obesity and diabetes become increasingly prevalent, the prevalence of CVD is also expected to rise.^2,3 Fortunately, many CVD events can be prevented or delayed by modifying risk factors such as hyperlipidemia, hypertension, and smoking. Interventions associated with a reduction in risk have led to a reduction in CVD events^4,5 and contributed to a steady decline in cardiac deaths.⁶

Control of platelet aggregation is a cornerstone of primary CVD prevention.⁷ In an outpatient setting, this usually translates into identifying patients who are at high risk for a CVD event and advising them to take low-dose aspirin daily or every other day. Although not without controversy,^8,9 the US Preventive Services Task Force (USPSTF) recommends regular aspirin use for primary CVD prevention for middle-aged to older men at high risk for myocardial infarction (MI) and women at high risk for ischemic stroke.¹⁰

The efficacy of this intervention is proven: In primary prevention trials, regular aspirin use is associated with a 14% reduction in the likelihood of CVD events over 7 years.¹¹ What’s more, aspirin therapy, as recommended by the USPSTF, is among the most cost-effective clinic-based preventive measures.¹²

In 2004, 41% of US adults age 40 or older reported taking aspirin regularly¹³—an increase of approximately 20% since 1999.¹⁴ More recent data from a national population-based cohort study found that 41% of adults ages 45 to 90 years who did not have CVD but were at moderate to high risk for a CVD event reported taking aspirin ≥3 days per week.¹⁵ In the same study, almost one-fourth of those at low CVD risk also reported regular aspirin use.

FAST TRACK

In a recent cohort study, 41% of adults ages 45 to 90 who did not have CVD but were at moderate to high risk for a CVD event reported taking aspirin ≥3 days per week.

While regular aspirin use for primary CVD prevention has been on the rise,^13,14 the extent to which this intervention has penetrated various segments of the population is unclear. Several studies have found that aspirin use is consistently highest among those who are older, male, and white.^15-17 Other socioeconomic variables (eg, education level, employment, marital status) have received little attention. And no previous study has used national guidelines for aspirin therapy to stratify samples.

A look at overuse and underuse. To ensure that aspirin therapy for primary CVD prevention is directed at those who are most likely to benefit from it, a better understanding of variables associated with both aspirin overuse and underuse is needed. This area of research is important, in part because direct-to-consumer aspirin marketing may be particularly influential among groups at low risk for CVD—for whom the risk of excess bleeding outweighs the potential for disease prevention.^13,18